Oncogenic KRAS Induces Arginine Auxotrophy and Confers a Therapeutic Vulnerability to SLC7A1 Inhibition in Non-Small Cell Lung Cancer [0.03%]
致癌KRAS诱导鸟氨酸辅助营养素缺乏并使非小细胞肺癌在SLC7A1抑制作用下产生治疗弱点
Xiameng Gai,Yingluo Liu,Xiaojing Lan et al.
Xiameng Gai et al.
The urea cycle is frequently rewired in cancer cells to meet the metabolic demands of cancer. Elucidation of the underlying mechanism by which oncogenic signaling mediates urea cycle reprogramming could help identify targetable metabolic vu...
Oncogenic Cell Tagging and Single-Cell Transcriptomics Reveal Cell Type-Specific and Time-Resolved Responses to Vhl Inactivation in the Kidney [0.03%]
致癌细胞标记和单细胞转录组学揭示VHL失活诱导的肾脏肿瘤发生过程中的细胞类型特异性和时间特异性反应
Samvid Kurlekar,Joanna D C C Lima,Ran Li et al.
Samvid Kurlekar et al.
Defining the initial events in oncogenesis and the cellular responses they entrain, even in advance of morphologic abnormality, is a fundamental challenge in understanding cancer initiation. As a paradigm to address this, we longitudinally ...
Cancer Cells Hijack Physiologic Metabolic Signals to Seed Liver Metastasis [0.03%]
癌细胞劫持生理性代谢信号在肝内形成转移病灶
Andres R Rettig,Karuna Ganesh
Andres R Rettig
Metastasis arises from cancer cell-intrinsic adaptations and permissive tumor microenvironments (TME) that are distinct across different organs. Deciphering the mechanisms underpinning organotropism could provide novel preventive and therap...
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation [0.03%]
ATG-101 是一种四价 PD-L1×4-1BB 双特异性抗体,可通过阻断 PD-L1 和激活由 PD-L1 介导的 4-1BB 来刺激抗肿瘤免疫反应
Hui Yuwen,Huajing Wang,Tengteng Li et al.
Hui Yuwen et al.
Immune checkpoint inhibitors (ICI) have transformed cancer treatment. However, only a minority of patients achieve a profound response. Many patients are innately resistant while others acquire resistance to ICIs. Furthermore, hepatotoxicit...
NCI Cancer Research Data Commons: Lessons Learned and Future State [0.03%]
国家癌症研究所癌症研究数据共享平台:经验教训与未来展望
Erika Kim,Tanja Davidsen,Brandi N Davis-Dusenbery et al.
Erika Kim et al.
More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations to better understand diseases and ultimately inform the development of better treatments and diagnostic ...
NCI Cancer Research Data Commons: Resources to Share Key Cancer Data [0.03%]
国家癌症研究所癌症研究数据共享平台:分享关键癌症数据的资源
Zhining Wang,Tanja M Davidsen,Gina R Kuffel et al.
Zhining Wang et al.
Since 2014, the NCI has launched a series of data commons as part of the Cancer Research Data Commons (CRDC) ecosystem housing genomic, proteomic, imaging, and clinical data to support cancer research and promote data sharing of NCI-funded ...
Arthur Brady,Amanda Charbonneau,Robert L Grossman et al.
Arthur Brady et al.
The NCI Cancer Research Data Commons (CRDC) is a collection of data commons, analysis platforms, and tools that make existing cancer data more findable and accessible by the cancer research community. In practice, the two biggest hurdles to...
David Pot,Zelia Worman,Alexander Baumann et al.
David Pot et al.
The NCI's Cloud Resources (CR) are the analytical components of the Cancer Research Data Commons (CRDC) ecosystem. This review describes how the three CRs (Broad Institute FireCloud, Institute for Systems Biology Cancer Gateway in the Cloud...
Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications [0.03%]
缩回:机制由SGN - 40,人源化抗- CD40抗体,诱导细胞毒性的在人的多发性骨髓瘤细胞:临床意义
Yu-Tzu Tai,Laurence P Catley,Constantine S Mitsiades et al.
Yu-Tzu Tai et al.
Retraction of Publication
Cancer research. 2024 Mar 15;84(6):936. DOI:10.1158/0008-5472.CAN-24-0520 2024
Retraction: Cancer-Associated PP2A Aα Subunits Induce Functional Haploinsufficiency and Tumorigenicity [0.03%]
撤稿声明:与癌症相关的PP2A Aα亚基诱导功能性杂合性不足和肿瘤形成能力
Wen Chen,Jason D Arroyo,Jamie C Timmons et al.
Wen Chen et al.
Retraction of Publication
Cancer research. 2024 Mar 15;84(6):935. DOI:10.1158/0008-5472.CAN-24-0434 2024